http://rdf.ncbi.nlm.nih.gov/pubchem/patent/LT-2001093-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-20 |
| filingDate | 2001-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32504e7a1a97ff29ff0fdd109fdcfa13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85d19a870e12217d675c793a7b011e57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5179af752db4a9e7031e1f442f5b932 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b9bc4b75bc351abeeeda66c0708690d |
| publicationDate | 2002-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | LT-2001093-A |
| titleOfInvention | INTERFERENCE ALFA PHARMACEUTICAL COMPOSITION |
| abstract | The invention relates to a solution of interferon alpha-2 (IFN) which exhibits increased thermal stability and auto-oxidation resistance and a method for its preparation. The solution contains (0.01-50) x 106 IU / ml interferon alfa-2b, 0.08-0.1 M sodium citrate, 0.05-0.06 M glycine, 0.008-0.01% polysorbate-20, 0.004-0.005% Thimerosal. The pH of the solution is maintained at 6.0 ± 0.1. The invention relates to the pharmaceutical field and may be used in the production and biotechnology of liquid pharmaceutical forms of IFN for the treatment of some viral and oncological diseases in the processes of genin engineering IFN. |
| priorityDate | 2001-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.